Bruush Oral Care Inc.

CIK:0001913210|SEC Filings

Statements of Comprehensive Loss - USD ($)	9 Months Ended	12 Months Ended
Statements of Comprehensive Loss - USD ($)	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Profit or loss [abstract]
Revenues	$ 1,965,441	$ 2,632,442	$ 901,162
Cost of goods sold	978,243	822,383	291,195
Gross Profit	987,198	1,810,059	609,967
Expenses
Advertising and marketing	2,806,260	7,162,046	2,670,447
Amortization and depreciation expense	5,498	15,348
Commission	26,339	91,050	11,207
Consulting	868,442	1,197,831	556,864
Interest and bank charges	60,183	1,155,288	18,130
Inventory management		47,405
Merchant fees	68,073	99,293	39,180
Office and administrative expenses	93,900	328,956	75,194
Professional fees	241,854	521,064	222,870
Research and development		96,431
Salaries and wages	282,003	1,222,171	93,460
Share-based compensation	92,276	279,622	4,949,441
Shipping and delivery	511,566	832,395	304,591
Travel and entertainment	100,068	259,372	29,225
Total expenses	(5,156,462)	(13,308,272)	(8,970,609)
Other items
Government grant	8,763		14,139
Foreign exchange	42,148	(153,076)	(7,719)
Gain (loss) on revaluation of warrant derivative	(92,918)	5,740,202	(536,209)
Financing costs		(2,688,034)
Other loss		(166,150)
Total other items	(42,007)	2,732,942	(529,789)
Net and comprehensive loss	$ (4,211,271)	$ (8,765,271)	$ (8,890,431)
Loss per share - Basic and diluted	$ (1.07)	$ (1.83)	$ (8.43)
Weighted average number of common shares outstanding - basic and diluted	3,929,520	4,800,972	1,054,371

Statements of Cash Flows - USD ($)	9 Months Ended	12 Months Ended
Statements of Cash Flows - USD ($)	Oct. 31, 2021	Oct. 31, 2022	Jan. 31, 2021
Cash flows from operating activities
Net loss	$ (4,211,271)	$ (8,765,271)	$ (8,890,431)
Items not affecting cash:
Amortization and depreciation	5,498	15,348
Government grant	(8,763)		(14,139)
Share-based compensation	92,276	279,622	4,949,441
Consulting	12,658	140,310
Loss (gain) on revaluation of warrant derivative	92,918	(5,740,202)	536,209
Interest expense	2,699	995,901	1,782
Unrealized foreign exchange	1,376	(1,771)	1,431
Financing costs		2,613,034
Accounts and other receivables	(79,888)	(14,209)	(68,190)
Inventory	402,130	589,037	(577,656)
Term deposit		(18,506)
Prepaid expenses and deposits	36,795	(652,161)	(114,917)
Accounts payable and accrued liabilities	3,057,343	(2,020,774)	31,999
Deferred revenue	(74,940)	(11,136)	92,121
Net cash flows used in operating activities	(671,169)	(12,590,778)	(4,052,350)
Cash flows from investing activities
Purchase of property and equipment	(6,201)	(2,042)	(3,196)
Purchase of intangible asset	(15,000)
Net cash flows used in investing activities	(21,201)	(2,042)	(3,196)
Cash flows from financing activities
Proceeds from promissory notes net of costs		3,860,750
Repayment of promissory notes		(4,852,867)
Proceeds from equity financings		15,510,764	4,973,023
Share issuance costs		(1,840,861)
Broker warrants		2,628
Repayment of loans		(29,203)	(433,987)
Proceeds from loans	14,253		28,506
Net cash flows provided by financing activities	14,253	12,651,211	4,567,542
Change in cash	(678,117)	58,391	511,996
Cash
Beginning of year	692,647	14,530	180,651
End of year	14,530	72,921	692,647
Supplemental cash flow disclosure
Interest		311,617
Taxes paid

Statements of Financial Position - USD ($)	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Current
Cash	$ 72,921	$ 14,530	$ 692,647
Term deposit	18,506
Accounts and other receivables	175,256	161,047	81,159
Inventory	241,341	774,117	1,176,247
Prepaid expenses and deposits	677,474	81,574	118,369
Total current assets	1,185,498	1,031,268	2,068,422
Non-current
Intangible asset		11,466
Property and equipment	5,619	7,432	3,196
Total assets	1,191,117	1,050,166	2,071,618
Current
Accounts payable and accrued liabilities	1,345,288	3,366,062	308,719
Loan payable		27,144	17,580
Deferred revenue	6,045	17,181	92,121
Warrant derivative	1,242,580	1,582,977	1,490,059
Total liabilities	2,593,913	4,993,364	1,908,479
SHAREHOLDERS’ EQUITY
Share capital	23,845,704	13,276,909	13,264,251
Reserves	1,137,814	400,936	308,660
Accumulated deficit	(26,386,314)	(17,621,043)	(13,409,772)
Total shareholders’ equity	(1,402,796)	(3,943,198)	163,139
Total liabilities and shareholders’ deficiency	$ 1,191,117	$ 1,050,166	$ 2,071,618